

ASX / Media Release

27 February 2009

RHT: Resonance Health announces 5th consecutive profitable quarter and continues to build expertise

The directors of Resonance Health Limited (ASX: RHT) are pleased to announce a profitable half year result with the release of 31 December 2008 results today. Highlights compared to the previous corresponding period (to 31 Dec 2007) include:

- **Total revenue up 28% to \$1.2m**
- **FerriScan[®] revenue up 16% to \$1.0m**
- **Expenditure down 33% to \$0.9m**
- **Half year profit of \$294,375 (from a loss of \$249,359)**
- **Cash and cash equivalents of \$2.7m**
- **5th consecutive profitable quarter**

Results for the period are very positive and commensurate with the company's strategy. Resonance Health has focused its spending on gaining reimbursement for FerriScan[®] in several countries and engaging key opinion leaders and primary centres of excellence for disease management.

The global financial crisis has had little impact on Resonance Health's operations. However, the Board and management continue to exercise considerable financial restraint in the current economic climate remaining focused on core activities including marketing and reimbursement of FerriScan[®] and the further development of FibroScreen[™]. As the majority of revenue is received in US dollars a foreign exchange gain has been recorded.

The company has also expanded its management team with the appointment of Ms Shameela Dermott to the position of Clinical Manager. Ms Dermott brings significant experience in the management of global clinical studies, engaging key opinion leaders, and reimbursement and has worked at international CROs in the UK and Europe.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@ferriscan.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. Its patented technology FerriScan[®], provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan[®] has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.